Ascelia Pharma

Executive Summary

Ascelia Pharma is a Swedish diagnostics company focused on developing innovative contrast agents for MRI, addressing the unmet need for safer alternatives to gadolinium-based agents. Its lead candidate, Orviglance (manganese-based), targets improved liver imaging with a favorable safety profile, particularly for patients with renal impairment. The company is currently in Phase 3 clinical development and has previously reported positive safety and efficacy data. Despite being private and without a public ticker, Ascelia's specialized pipeline and potential to disrupt the contrast agent market position it as a notable player in the diagnostics space. However, the lack of recent public updates and early-stage revenue profile suggest higher risk.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data for Orviglance in Liver Imaging65% success
• Q4 2026Regulatory Submission (NDA/EMA) for Orviglance60% success
• TBDStrategic Partnership or Licensing Deal for Orviglance40% success